These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36560708)

  • 1. Targeting a Conserved Lysine in the Hydrophobic Pocket of HIV-1 gp41 Improves Small Molecule Antiviral Activity.
    He L; Zhou G; Sofiyev V; Garcia E; Nguyen N; Li KH; Gochin M
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
    Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
    Li W; Lu L; Li W; Jiang S
    Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A targeted covalent small molecule inhibitor of HIV-1 fusion.
    Zhou G; He L; Li KH; Pedroso CCS; Gochin M
    Chem Commun (Camb); 2021 May; 57(37):4528-4531. PubMed ID: 33956029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
    J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphipathic properties of HIV-1 gp41 fusion inhibitors.
    Gochin M; Zhou G
    Curr Top Med Chem; 2011 Dec; 11(24):3022-32. PubMed ID: 22044226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational flexibility of the conserved hydrophobic pocket of HIV-1 gp41. Implications for the discovery of small-molecule fusion inhibitors.
    Cano-Muñoz M; Jurado S; Morel B; Conejero-Lara F
    Int J Biol Macromol; 2021 Dec; 192():90-99. PubMed ID: 34619276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.
    He Y; Liu S; Jing W; Lu H; Cai D; Chin DJ; Debnath AK; Kirchhoff F; Jiang S
    J Biol Chem; 2007 Aug; 282(35):25631-9. PubMed ID: 17616522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.
    Liu K; Lu H; Hou L; Qi Z; Teixeira C; Barbault F; Fan BT; Liu S; Jiang S; Xie L
    J Med Chem; 2008 Dec; 51(24):7843-54. PubMed ID: 19053778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
    Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
    Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
    Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
    Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of HIV-1 fusion inhibitors targeting gp41.
    Lu K; Asyifah MR; Shao F; Zhang D
    Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.
    Zhang X; Zhu Y; Hu H; Zhang S; Wang P; Chong H; He J; Wang X; He Y
    Front Cell Infect Microbiol; 2018; 8():51. PubMed ID: 29535974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.
    Zhou G; Wu D; Snyder B; Ptak RG; Kaur H; Gochin M
    J Med Chem; 2011 Oct; 54(20):7220-31. PubMed ID: 21928824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.